Wang Ziyun, Wang Hua
Department of Breast and Thyroid Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Front Oncol. 2024 Apr 19;14:1374696. doi: 10.3389/fonc.2024.1374696. eCollection 2024.
Prolyl 3-hydroxylases (P3H) are crucial enzymes in collagen biosynthesis and are known to be involved in a variety of physiological processes. However, their specific roles in cancer progression, modulation of the tumor microenvironment (TME), and impact on patient prognosis remain areas that require further investigation.
The investigation involved a comprehensive analysis of expression profiles and clinical data obtained from the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases. This included the assessment of genetic variation, gene expression, and the prognostic significance of P3H family genes. P3H scores were calculated using various databases and R-based tools, followed by correlation analyses with the TME, immune cell infiltration, drug sensitivity and immunotherapy.Variations in P3H gene expression patterns were observed across different tumor types and prognoses, suggesting that most genes within the family were risk factors, especially P3H1 and P3H4. The P3H score was associated with immune infiltration and drug resistance. Notably, individuals with elevated expression of P3H2, P3H3, and CRTAP exhibited higher resistance to multiple anti-tumor drugs.
P3H family proteins play diverse roles in cancer progression, significantly impacting patient prognosis and the effectiveness of immunotherapy.
The P3H score, identified as a potential biomarker for evaluating TME, holds promise in guiding precision medicine strategies.
脯氨酰3-羟化酶(P3H)是胶原蛋白生物合成中的关键酶,已知其参与多种生理过程。然而,它们在癌症进展、肿瘤微环境(TME)调节以及对患者预后的影响等方面的具体作用仍需进一步研究。
该研究对从基因型-组织表达(GTEx)和癌症基因组图谱(TCGA)数据库获得的表达谱和临床数据进行了全面分析。这包括对P3H家族基因的遗传变异、基因表达及预后意义的评估。使用各种数据库和基于R的工具计算P3H评分,随后与TME、免疫细胞浸润、药物敏感性和免疫治疗进行相关性分析。在不同肿瘤类型和预后中观察到P3H基因表达模式的差异,表明该家族中的大多数基因是危险因素,尤其是P3H1和P3H4。P3H评分与免疫浸润和耐药性相关。值得注意的是,P3H2、P3H3和CRTAP表达升高的个体对多种抗肿瘤药物表现出更高的耐药性。
P3H家族蛋白在癌症进展中发挥多种作用,对患者预后和免疫治疗效果有显著影响。
P3H评分被确定为评估TME的潜在生物标志物,有望指导精准医学策略。